SEC Form 4 · accession 0001640455-18-000086
Jounce Therapeutics, Inc. · JNCE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Kamen
Director
Period of report
Jun 19, 2018
Accepted (ET)
Jun 21, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001640455
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.92 | Jun 19, 2018 | A | 13,550 | A | — | Jun 19, 2028 | Common Stock | 13,550 | 13,550 | D |
Explanation of responses
- F1The option will vest in equal quarterly installments during the four quarters following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.